ProVise Management Group LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,829 shares of the medical instruments supplier’s stock, valued at approximately $358,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Mawer Investment Management Ltd. raised its holdings in shares of Becton, Dickinson and by 1.4% in the third quarter. Mawer Investment Management Ltd. now owns 1,799,828 shares of the medical instruments supplier’s stock valued at $352,599,000 after buying an additional 24,761 shares during the last quarter. SPF Beheer BV raised its holdings in Becton, Dickinson and by 6.5% during the 3rd quarter. SPF Beheer BV now owns 388,447 shares of the medical instruments supplier’s stock worth $76,116,000 after purchasing an additional 23,559 shares during the last quarter. Harbour Capital Advisors LLC bought a new stake in Becton, Dickinson and during the 3rd quarter worth about $271,000. Meiji Yasuda Asset Management Co Ltd. raised its holdings in Becton, Dickinson and by 1.3% during the 3rd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 23,129 shares of the medical instruments supplier’s stock worth $4,532,000 after purchasing an additional 300 shares during the last quarter. Finally, Findlay Park Partners LLP raised its holdings in Becton, Dickinson and by 2.3% during the 3rd quarter. Findlay Park Partners LLP now owns 1,765,000 shares of the medical instruments supplier’s stock worth $345,852,000 after purchasing an additional 40,000 shares during the last quarter. 87.91% of the stock is owned by institutional investors and hedge funds.

In related news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the transaction, the insider now owns 14,038 shares of the company’s stock, valued at $2,814,057.48. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company (NYSE BDX) traded up $5.33 during trading on Wednesday, hitting $226.83. The stock had a trading volume of 1,476,500 shares, compared to its average volume of 1,323,648. The firm has a market cap of $50,405.64, a price-to-earnings ratio of 23.34, a P/E/G ratio of 1.73 and a beta of 1.04. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $227.50. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.12 EPS. equities research analysts expect that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a $0.75 dividend. The ex-dividend date is Thursday, December 7th. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a dividend yield of 1.32%. Becton, Dickinson and’s payout ratio is currently 62.80%.

BDX has been the subject of several recent research reports. Wells Fargo & Company reissued a “positive” rating and set a $235.00 price objective (up from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Morgan Stanley boosted their price objective on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $230.00 price objective (up from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $217.08.

WARNING: “ProVise Management Group LLC Purchases New Holdings in Becton, Dickinson and Company (BDX)” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/22/provise-management-group-llc-purchases-new-holdings-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.